34. Neurofibromatosis
120 clinical trials,   182 drugs   (DrugBank: 72 drugs),   84 drug target genes,   194 drug target pathways
Searched query = "Neurofibromatosis", "NF1", "von Recklinghausen disease", "NF2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03826940 (ClinicalTrials.gov) | February 19, 2019 | 23/1/2019 | From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 | Linking Inhibition From Molecular to Systems and Cognitive Levels: a Preclinical and Clinical Approach in Autism Spectrum Disorders and Neurofibromatosis. | Autism Spectrum Disorder;Neurofibromatosis 1 | Drug: Lovastatin 60 MG;Drug: Placebos | University of Coimbra | NULL | Recruiting | 16 Years | 65 Years | All | 30 | N/A | Portugal |